CSL expresses confidence on HAE patent

Australia’s CSL Limited (ASX: CSL) says it has become aware that Shire ViroPharma has filed a complaint in the US District Court for the District of Delaware alleging infringement of a newly-granted US patent in connection with a method of treating hereditary angioedema (HAE) by subcutaneously administering C1-esterase inhibitor.

CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma, a unit of Ireland-headquartered Shire (LSE: SHP), patent and will vigorously defend against the claims.

In August 2016, the US Food and Drug Administration  accepted for review CSL’s Biologics License Application for CSL830, the firm’s low-volume subcutaneous C1-esterase inhibitor (human) replacement therapy for the prevention of HAE attacks. This work is the product of independent research and development work at CSL Behring.